Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

$30.15 +2.28 (+8.18%)

(As of 11/20/2024 ET)

Tandem Diabetes Care - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 18 Analyst Ratings

Sell
0

Hold
4

Buy
14

Based on 18 Wall Street analysts who have issued ratings for Tandem Diabetes Care in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 4 have given a hold rating, and 14 have given a buy rating for TNDM.

Consensus Price Target

$54.25
79.93% Upside

According to the 18 analysts' twelve-month price targets for Tandem Diabetes Care, the average price target is $54.25. The highest price target for TNDM is $75.00, while the lowest price target for TNDM is $37.00. The average price target represents a forecasted upside of 79.93% from the current price of $30.15.

Get the Latest News and Ratings for TNDM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Tandem Diabetes Care and its competitors.

TNDM Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	5 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$54.25	$55.13	$54.36	$38.50
Forecasted Upside	79.93% Upside	64.38% Upside	21.88% Upside	102.21% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

TNDM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TNDM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Tandem Diabetes Care Stock vs. The Competition

Type	Tandem Diabetes Care	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	79.93% Upside	26,931.54% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent TNDM News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	Barclays 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$58.00 ➝ $60.00	+92.86%
11/7/2024	Canaccord Genuity Group 1 of 5 stars		Lower Target	Buy ➝ Buy	$57.00 ➝ $56.00	+67.16%
11/7/2024	Robert W. Baird 2 of 5 stars		Lower Target	Neutral ➝ Neutral	$39.00 ➝ $37.00	+9.89%
11/6/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Hambright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$42.00	+26.85%
10/4/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$46.00	+13.69%
10/2/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00	+58.27%
Get the Latest News and Ratings for TNDM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.
9/23/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight ➝ Equal Weight	$45.00 ➝ $45.00	-2.24%
8/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/2/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$50.00 ➝ $55.00	+31.86%
8/2/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $55.00	+29.35%
6/10/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$47.00 ➝ $58.00	+18.73%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+15.94%
5/22/2024	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$60.00 ➝ $75.00	+47.17%
5/22/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $55.00	+11.52%
5/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$40.00 ➝ $57.00	+15.57%
4/25/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$34.00 ➝ $45.00	+28.13%
10/2/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$47.00 ➝ $45.00	+116.66%
8/4/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$52.00 ➝ $34.00	+2.87%
6/13/2023	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$74.00 ➝ $50.00	+93.12%
5/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$45.00 ➝ $33.00	-12.02%
4/24/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
2/23/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$61.00 ➝ $52.00	+29.84%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:03 AM ET.

TNDM Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Tandem Diabetes Care is $54.25, with a high forecast of $75.00 and a low forecast of $37.00.
: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 4 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TNDM shares.
: According to analysts, Tandem Diabetes Care's stock has a predicted upside of 79.93% based on their 12-month stock forecasts.
: Tandem Diabetes Care has been rated by research analysts at Barclays, Canaccord Genuity Group, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, and The Goldman Sachs Group in the past 90 days.
: Analysts like Tandem Diabetes Care less than other "medical" companies. The consensus rating score for Tandem Diabetes Care is 2.78 while the average consensus rating score for "medical" companies is 2.80. Learn more on how TNDM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NASDAQ:TNDM) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Stock Forecast & Price Target